BMS Adds Nucleotide Analogue to its HCV Pipeline with US$2.5 B Inhibitex Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)
Published: 12 Jan-2012
DOI: 10.3833/pdr.v2012.i1.1667 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Impressed by positive Phase Ib results of its hepatitis C virus (HCV) nucleotide polymerase inhibitor INX-189, Bristol-Myers Squibb (BMS) has agreed to purchase Inhibitex for US$26 per share in a deal that values the company at approximately US$$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS